

RNA/MBNL1-containing foci in myoblast nuclei from patients affected by myotonic dystrophy type 2: an immunocytochemical study

F. Perdoni,¹ M. Malatesta,² R. Cardani,^{3,4} M. Giagnacovo,³ E. Mancinelli,³ G. Meola,⁵ C. Pellicciari¹

¹Dipartimento di Biologia Animale, Laboratorio di Biologia cellulare e Neurobiologia, Università di Pavia, Italy; ²Dipartimento di Scienze Morfologico-Biomediche, Sezione di Anatomia e Istologia, Università di Verona, Italy; ³Dipartimento di Biologia molecolare e Biotecnologie, ⁴Centro per lo studio delle Malattie Neuromuscolari-CMN, and ⁵Dipartimento di Neurologia, IRCCS Policlinico San Donato, Università degli Studi di Milano, Italy



©2009 European Journal of Histochemistry

Myotonic dystrophy type 2 (DM2) is a dominantly inherited autosomal disease with multi-systemic clinical features and it is caused by expansion of a CCTG tetranucleotide repeat in the first intron of the zinc finger protein 9 (ZNF9) gene in 3q21. The expanded-CCUG-containing transcripts are retained in the cell nucleus and accumulate in the form of focal aggregates which specifically sequester the muscleblind-like 1 (MBNL1) protein, a RNA binding factor involved in the regulation of alternative splicing. The structural organization and composition of the foci are still incompletely known. In this study, the nuclear foci occurring in cultured myoblasts from DM2 patients were characterised at fluorescence and transmission electron microscopy by using a panel of antibodies recognizing transcription and processing factors of pre-mRNAs. MBNL1 proved to co-locate in the nuclear foci with snRNPs and hnRNPs, whereas no co-location was observed with RNA polymerase II, the non-RNP splicing factor SC35, the cleavage factor CStF and the PML protein. At electron microscopy the MBNL1-containing nuclear foci appeared as roundish domains showing a rather homogeneous structure and proved to contain snRNPs and hnRNPs. The sequestration of splicing factors involved in early phases of pre-mRNA processing supports the hypothesis of a general alteration in the maturation of several mRNAs, which could lead to the multiple pathological dysfunctions observed in dystrophic patients.

Key words: myotonic dystrophy type 2 - DM2, myoblast, immunocytochemistry, fluorescence microscopy, electron microscopy, RNA processing.

Correspondence: Carlo Pellicciari,
Dipartimento di Biologia Animale, Università degli Studi di Pavia, Piazza Botta, 10 27100 Pavia, Italy
E-mail: pelli@unipv.it

Paper accepted on July 17, 2009

European Journal of Histochemistry
2009; vol. 53 issue 3 (July-September): 151-158

Myotonic dystrophy type 2 (DM2) is a dominantly inherited autosomal disease with multi-systemic clinical features and it is caused by expansion of a CCTG tetranucleotide repeat in the first intron of the zinc finger protein 9 (ZNF9) gene in 3q21 (Liquori *et al.*, 2001; Ranum and Day, 2004). The expanded-CCUG-containing transcripts are retained in the cell nucleus and accumulate in the form of focal aggregates (Liquori *et al.*, 2001). These aggregates are a biomolecular feature of DMs and have been evidenced in several adult tissues and cell cultures by *in situ* hybridization (Taneja *et al.*, 1995; Liquori *et al.*, 2001; Mankodi *et al.*, 2003, 2005; Jiang *et al.*, 2004; Schoser *et al.*, 2004; Wheeler *et al.*, 2007; Cardani *et al.*, 2004, 2009). The nuclear foci of mutant mRNA specifically sequester muscleblind-like (MBNL) proteins, i.e. essential splicing factors (Pascual *et al.*, 2006), leading to nuclear depletion and a loss of function of these regulators (Mankodi *et al.*, 2001). MBNL proteins are therefore good markers for the DM2-specific RNA-containing nuclear aggregates (Mankodi *et al.*, 2001; Fardaei *et al.*, 2002; Cardani *et al.*, 2006, 2009). Sequestration of RNA binding proteins is thought to alter the splicing of a large set of pre-mRNAs, including transcripts of the insulin receptor, CIC-1 chloride channel, and other genes relevant to the clinical manifestations (Mankodi *et al.*, 2002; Savkur *et al.*, 2004). Margolis *et al.* (2006) demonstrated that DM2 foci contain the expanded CCUG tract with no other portions of the ZNF9 transcript. This repetitive RNA persists in the nucleus even after other parts of the intron have been degraded because it has a stable secondary structure or because it is tightly associated with binding proteins (Dere *et al.*, 2004; Margolis *et al.*, 2006; Ranum and Cooper, 2006).

The molecular composition of nuclear foci is far

from being fully elucidated, but it is likely to hypothesize that other proteins involved in RNA processing may be sequestered therein, with a possible rebound on the overall nuclear function.

The effective role of nuclear foci in DM disease process is still debated. Recently Junghans (2009) has published his viewpoint on this item in which he discusses if foci may reflect the disease or if may be causative to DM pathogenesis. Studies on molecular composition and mechanisms of formation of nuclear foci may better explain the real role of these aggregates in the disease process.

In eukaryotic cells, transcription and splicing take place inside nuclear RNA-containing structures recognized, at electron microscopy, as perichromatin fibrils (PF), perichromatin granules (PG), and interchromatin granules (IG) (Spector, 1996; Fakan, 2004). PF are the morphological equivalent of hnRNA transcription and co-transcriptional splicing, while IG represent a storage site for small nuclear RNPs (snRNPs) and non-snRNP splicing factors, and PG are involved in the storage and the nucleus-to-cytoplasm transport of mRNA (recently reviewed in Biggiogera *et al.*, 2007). PF and PG locate at the periphery of condensed chromatin, and IG in the so-called interchromatin space (for a review, see Puvion and Puvion-Dutilleul, 1996): this is a necessary prerequisite for the maturation of nuclear RNAs, so that whenever transcription and/or splicing are altered, the organization, composition, and intranuclear location of RNP-containing structures are affected too (Biggiogera *et al.*, 2004, 2007). It has been shown that transcriptional arrest (irrespective of its physiological or induced origin: Biggiogera *et al.*, 2004) results in the formation of heterogeneous ectopic RNP-derived structures (HERDS) which contain two or more RNP components that normally do not collocate (Biggiogera *et al.*, 1998; Biggiogera and Pellicciari, 2000). The accumulation within HERDS of RNA and protein factors involved in the processing of nuclear RNAs actually blocks the maturation and export of mRNAs.

The aim of this study was to investigate by means of fluorescence and immunoelectron microscopy the molecular composition of DM2 nuclear foci, in the attempt to elucidate whether other protein besides MBNL might be present therein. Using cultured myoblasts from DM2 patients we have also described, for the first time, the ultrastructural features of the RNA-containing nuclear foci.

Materials and Methods

Sample collection and cell culture

The biopsies used in this study were taken, under sterile conditions, from the *biceps brachii* of four DM2 patients, after informed consent. The histological diagnosis was performed on serial sections processed for routine histological or histochemical staining, based on the clinical criteria set by the International Consortium for Myotonic Dystrophies (Moxley *et al.*, 2002). The biopsies from donors were trimmed of blood vessels, fat and connective tissues, and rinsed in phosphate-buffered saline (PBS); satellite cells were isolated as reported in Cardani *et al.* (2009) and placed in HAM's F10 medium (Sigma-Aldrich, Buchs, Switzerland) supplemented with 15% fetal bovine serum (Gibco, Invitrogen, Italy), 0.5 mg/mL albumin from bovine serum (BSA, Sigma - Aldrich), 0.5 mg/mL fetuin, 0.39 µg/mL dexamethasone, 10 ng/ml epidermal growth factor, 0.05 mg/mL insulin, 3 mg/mL glucose, 100 U/mL penicillin and 100 µg/ml streptomycin (Sigma - Aldrich). The myoblasts obtained by this procedure were propagated in plastic flasks at 37°C in a humidified 95% air/5% CO₂ atmosphere. For transmission electron microscopy, the myoblasts were fixed in the flasks and then collected by scraping, whereas for light microscopy they were previously planted on glass coverslips to be processed for fluorescence *in situ* hybridization (FISH) and immunocytochemistry (see below).

Fluorescence microscopy

For fluorescence *in situ* hybridization (FISH) and immunocytochemistry, myoblasts were fixed with 2% formaldehyde in PBS for 30 min at 4°C.

For FISH, a Texas red labelled (CAGG)₅ probe (IDT, Coralville, IA, USA) was used as previously reported by Cardani *et al.* (2004, 2009). Briefly, fixed myoblasts were permeabilized with 2% acetone in PBS (pre-chilled at -20°C) for 5 min. After washing in PBS, sections were incubated in 30% formamide and 2xSSC for 10 min at room temperature (r.t.), and then hybridized with the probe (1 ng/µL) for 2 h at 37°C in 30% formamide, 2xSSC, 0.02% BSA, 67 ng/µL yeast tRNA, 2 mM vanadyl ribonucleoside complex. Cells were washed in 30% formamide and 2xSSC at 45°C for 30 min, washed five times in PBS for 3 min at r.t., and pre-incubated with normal goat serum (DAKO, Glostrup, Denmark) at a dilution 1:20 in PBS containing 2%

BSA for 20 min at r.t.. Immunolabelling for MBNL1 protein was performed using a rabbit polyclonal anti-MBNL1 (kind gift of Prof. C. A. Thornton, University of Rochester, NY, USA) at a dilution of 1:1000 in PBS containing 2% BSA, for 2 hr at r.t., then revealed with an Alexa 488-labelled goat anti-rabbit antibody (Molecular Probes, Invitrogen, Italy) diluted 1:200 in PBS containing 2% BSA for 1 h at r.t.. After incubation, the cells were stained for DNA with 165 nM 4,6-diamidino-2-phenylindole (DAPI) in PBS at r.t. for 30 min, and finally mounted with ProLong (Molecular Probes, Invitrogen).

To get information on the intranuclear location of the RNA-containing foci and their composition, a panel of antibodies directed against MBNL1 or transcription, splicing or cleavage factors were used in dual-immunolabelling experiments (Table 1); secondary antibodies labelled with different fluorochromes were used. Briefly, 2% formaldehyde-fixed myoblasts were post-fixed with cold 70% ethanol, and incubated with the primary and the appropriate secondary antibodies (for 2 h and 1 h respectively, at r.t.); immunolabelled myoblasts were stained for DNA with 0.1 µg/mL of Hoechst 33258 in PBS (10 min at r.t.), and finally mounted in a drop of Mowiol (Calbiochem, Milan, Italy).

As negative controls, some slides were processed as described above, but omitting the incubation with the primary antibodies.

An Olympus BX51 microscope equipped with a

100W mercury lamp was used under the following conditions: 330-385 nm excitation filter (excf), 400-nm dichroic mirror (dm), and 420-nm barrier filter (bf), for Hoechst 33258 or DAPI; 450-480 nm excf, 500-nm dm, and 535 nm±20 nm band-pass filter, for the fluorescence of Alexa 488; 540 nm excf, 580 nm dm, and 620 nm bf for Alexa 594 or Texas red. Images were recorded with an Olympus MagniFire camera system, and processed with the Olympus CellF software (Olympus Italia Srl, Segrate, Italy).

Transmission electron microscopy

For conventional morphology, cells were fixed with 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M Sörensen phosphate buffer at 4°C for 1 h, washed, post-fixed with 1% OsO₄ at 4°C for 30 min, dehydrated with acetone and embedded in Epon. For immunoelectron microscopy, cells were fixed with a mixture of 4% paraformaldehyde and 0.2% glutaraldehyde in 0.1 M Sörensen phosphate buffer at 4°C for 1 h, washed, treated with NH₄Cl 0.5 M in PBS, dehydrated with ethanol and embedded in Unicryl resin.

Ultrathin sections from Epon-embedded samples were conventionally stained with uranyl acetate and lead citrate.

Ultrathin sections from Unicryl-embedded samples were placed on nickel grids and processed for immunocytochemistry with the same anti-MBNL1 antibody used for fluorescence microscopy. Sections

Table 1. Features of the antibodies used for immunofluorescence analyses.

Antibody	Origin	Antigen	Dilution	Secondary marker	Reference - Source
Anti-C8V	chicken polyclonal	hnRNP core proteins	1:1000	Alexa 594 labelled Goat anti-chicken IgG	Jones <i>et al.</i> , 1980
Anti-Sm	mouse monoclonal	Sm antigen (U ₁ , U ₂ , U ₄ , U ₅ snRNP)	1:100	Alexa 594 labelled Goat anti-mouse IgG	Abcam (Cambridge, UK)
Anti-SC35	mouse monoclonal	SC-35 non snRNP splicing factor	1:200	Alexa 594 labelled Goat anti-mouse IgG	Sigma Chem Co. (St. Louis MO, USA)
Anti-CSF	chicken polyclonal	Cleavage stimulation factor	1:2000	Alexa 594 labelled Goat anti-chicken IgG	Veraldi <i>et al.</i> , 2001
Anti-RNA polymerase II (clone H14)	mouse monoclonal	Phosphorylated (activated) form of RNA polymerase II	1:100	Alexa 594 labelled Goat anti-mouse IgG	Research Diagnostics Inc. (Concorde MA, USA)
Anti-PML	mouse monoclonal	Human PML protein	1:200	Alexa 594 labelled Goat anti-mouse IgG	Santa Cruz Biotechnology (Santa Cruz CA, USA)

were floated on normal goat serum (NGS) diluted 1:100 in PBS and incubated overnight at 4°C with the primary antibody diluted 1:50 in a solution containing 0.1% BSA and 0.05% Tween 20 in PBS. After rinsing, sections were floated in NGS and then reacted for 20 min with the specific gold-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA) diluted 1:10 in PBS. Finally, the sections were rinsed and air dried. As controls, some grids were treated with the incubation mixture without the primary antibody and then processed as described above.

Moreover, in order to confirm the apparent co-location of MBNL1 with some splicing factors as observed by immunofluorescence microscopy (see the section Results), myoblast samples were also dual-immunolabelled by combining the anti-MBNL1 antibody with antibodies directed against either the Sm complex of U1, U2, U5 and U4/U6 snRNPs (Abcam, Cambridge, MA) or the heterogeneous nuclear RNP (hnRNP) core protein (Jones *et al.*, 1980), according to the procedure described above.

To reduce chromatin contrast and selectively reveal nuclear RNP constituents, the sections were treated according to the EDTA method (Bernhard, 1969), and then observed in a Philips Morgagni TEM operating at 80kV and equipped with a Megaview II camera for digital image acquisition.

Results

Fluorescence microscopy

In DM2 myoblasts, MBNL1 proved to be present in discrete dots (which correspond to the expanded-CCUG-containing foci: Figure 1) as well as in a weakly fluorescing diffused form throughout the nucleoplasm (consistent with the intranuclear location of splicing factors). Dual immunolabelling experiments demonstrated that MBNL1 does not co-locate in the foci with the non-snRNP splicing factor SC35 (Figure 2) and the PML protein (Figure 3); similar results were obtained also for RNA polymerase II and the cleavage factor CStF (*not shown*).

On the contrary, the hnRNP core protein (Figure 4) and the snRNP Sm antigen (Figure 5) were observed in some of the MBNL1-positive foci. Interestingly enough, the immunolabelling for these RNPs appeared as a ring-shaped fluorescence pattern around the brightly fluorescing MBNL1-containing core (insets of Figure 4 and 5). In addition, some co-location for the hnRNP core protein and for the Sm antigen was also observed to occur also in the nucleoplasm (Figure 4 and 5).

Fluorescent labelling was negligible in the negative controls (*not shown*).

Transmission electron microscopy

At electron microscopy, myoblast nuclei showed




Figure 1. In the myoblast nuclei, the immunolabelling for MBNL1 (green fluorescence in a) and the signal of *in situ* hybridization for the mutant mRNA containing CCUG repeats (red fluorescence in b) co-locate (yellow fluorescence in the merged image, c). DNA was counterstained with DAPI (blue fluorescence). Bar: 10 μ m.




Figure 2. The immunolabelling for MBNL1 (green fluorescence in a) and that for the non-snRNP splicing factor SC35 (red fluorescence in b) do not co-localize (merged image, c). DNA was counterstained with Hoechst 33258 (blue fluorescence in a, b). Bar: 10 μ m.

Figure 3. The immunolabelling for MBNL1 (green fluorescence in a) and that for the PML protein (red fluorescence in b) do not co-localize (merged image, c). DNA was counterstained with Hoechst 33258 (blue fluorescence in a, b). Bar: 10 μ m.

Figure 4. The immunolabelling for MBNL1 (green fluorescence in a) and that for the hnRNP core protein (red fluorescence in b) co-localize (yellow fluorescence in the merged image, c). DNA was counterstained with Hoechst 33258 (blue fluorescence in a, b). Bar: 10 μ m. In the insets, the co-labelled focus indicated by the arrow is shown at a higher magnification.

Figure 5. The immunolabelling for MBNL1 (green fluorescence in a) and that for the snRNP Sm antigen (red fluorescence in b) co-localize (yellow fluorescence in the merged image, c). DNA was counterstained with Hoechst 33258 (blue fluorescence in a, b). Bar: 10 μ m. In the insets, the co-labelled focus indicated by the arrow is shown at a higher magnification.

small condensed chromatin clumps (mainly at the nuclear periphery), PG and abundant PF preferentially located at the hedge of condensed chromatin, and small clusters of IG in the interchromatin space; the nucleoli were large with a few fibrillar centres surrounded by the dense fibrillar component and a prominent granular component (Figure 6). In addition to the usual structural constituents, roundish nuclear domains (100-200 nm in diameter) were observed in about 20% of the sectioned nuclei: in Epon-embedded samples they appeared as roundish homogeneously strong electron-dense structures (Figure 4), while in the Unicryl-embedded and EDTA-treated samples they appeared as less electron-dense irregularly sized domains surrounded by fine fibrils spreading out at their periphery (Figure 7). They always occurred in the interchromatin space. The gold-immunolabelling for MBNL1 specifically occurred on PF and was found to accumulate in the nuclear domains described above (Figure 7a). Consistent with the evidence in fluorescence microscopy, MBNL1 was observed to co-locate in the foci with hnRNPs (Figure 7b) and with the snRNP Sm antigen (Figure 7c). On the thin sections, however, the gold grains labelling these RNPs were distributed all over the foci and not at the periphery only.

Background values were negligible in all immunolabelling experiments (*not shown*).




Figure 6. Myoblast nucleus, glutaraldehyde fixation, OsO₄ post-fixation, Epon embedding. A strongly electron-dense roundish nuclear domain (arrow) occurs in the nucleoplasm. Ch: condensed chromatin; Nu: nucleolus. Bar: 1 μ m.

Discussion

Combining fluorescence and immunoelectron microscopy on DM2 cultured myoblasts, we obtained information on the molecular composition of the typical nuclear foci: the expanded-CCUG-containing transcripts accumulate; in addi-




Figure 7. Myoblast nuclei, paraformaldehyde fixation, Unicryl-embedding, EDTA staining. (a) Immunolabelling with anti-MBNL1 antibody: the signal accumulates in the RNP nuclear domain (arrows) and is also associated with PF (arrowheads). (b) Dual immunolabelling with anti-MBNL1 (12 nm) and anti-snRNP (6 nm) antibodies; (c) dual immunolabelling with anti-MBNL1 (18 nm) and anti-hnRNP (12 nm) antibodies: in both cases the probes co-locate in the RNP nuclear domain (arrow) and on PF (arrowheads). Bars: 250 nm (a-c); 100 nm (insets).

tion these foci were recognized as distinct nuclear domains at the ultrastructural level.

Experiments of simultaneous *in situ* hybridization and immunolabelling confirmed that in cultured myoblasts the mutant RNA-containing nuclear foci sequester the splicing factor MBNL1 (Cardani *et al.*, 2009), thus indicating that the molecular features observed in DM2 adult tissues are reproduced in *in vitro* muscle cells (Mankodi *et al.*, 2003; Cardani *et al.*, 2004; Schoser *et al.*, 2004).

The RNA-containing nuclear foci observed at fluorescence microscopy can be also recognized at electron microscopy as roundish electron-dense domains which do contain RNPs (as demonstrated by the EDTA regressive staining), and proved to be immunopositive for MBNL1. These nuclear domains are always surrounded by PF but never occur in proximity of IG clusters, consistent with previous observations by immunofluorescence techniques (Holt *et al.*, 2007). They morphologically resemble the so-called amorphous bodies, i.e., RNP-containing nuclear aggregates which accumulate in several Vertebrate tissues during hibernation, and are storage sites for many protein factors involved in pre-mRNA processing (e.g., Malatesta *et al.*, 1994, 1999, 2006). The diffuse immunolabelling for MBNL1 observed in myoblast nuclei at fluorescence microscopy was found to correspond to the ultrastructural labelling of PF, where transcription and early splicing of pre-mRNA take place (Fakan, 2004); this distribution is in agreement with the functional role of MBNL1 as an RNA-binding protein involved in the regulation of alternative splicing (Pascual *et al.*, 2006). Fluorescence dual-immunolabelling experiments demonstrated that RNA polymerase II, the non-snRNP splicing factor SC35, the cleavage factor CStF, and the PML protein do not co-locate with MBNL1 in the foci, whereas a co-occurrence herein was observed for the hnRNP core protein and the snRNP Sm antigen. This co-location was confirmed by immunoelectron microscopy not only on the RNP-containing nuclear domains but also on PF; this latter finding corresponds to the diffuse co-location observed at light microscopy. Interestingly, in electron micrographs the labelling for hnRNPs and snRNPs was distributed over the whole nuclear domains, whereas at fluorescence microscopy a bright ring-shaped signal for hnRNPs or snRNPs was found to surround the MBNL1-rich core of the foci. To explain this inconsistency, one should con-

sider that at electron microscopy the antibodies can interact with their antigens even *inside* the foci, since the immunolabelling is performed on sections; on the contrary, whole cells are used for the immunofluorescent labelling, so that the penetration of the probe could be hindered by the apparently dense structure of the RNP-containing foci. The intense fluorescence for hnRNPs and snRNPs around the foci could also be explained by the high content in these two splicing factors on PF which surround the MBNL1-containing core. The presence of hnRNPs and snRNPs indicates that the DM2-specific nuclear foci share similarities in their molecular composition with both the amorphous bodies and the HERDS, i.e., the heterogeneous aggregates containing at least two nuclear RNA-associated protein factors which usually do not co-locate. Amorphous bodies form during hibernation, when the transcription and splicing rate is drastically reduced, and disassemble upon arousal, releasing the pre-mRNA processing factors accumulated therein, in order to rapidly resume the nuclear activities (Malatesta *et al.*, 2001). HERDS were observed in different cell systems, whenever RNA transcription is altered, and have been suggested as a possible marker of transcriptional arrest (Biggiogera and Pellicciari, 2000): under normal conditions, a balance exists between the amount of newly synthesized pre-mRNA and the proteins involved in their processing but, if the amount of newly formed hnRNA decreases, RNA-associated proteins become exceedingly predominant and accumulate in HERDS. The present results suggest that an exceeding amount of RNA (i.e., the expanded-CCUG-containing transcripts retained in the nucleus of DM2 cells) can determine the sequestration in the foci not only of MBNL1 but also of other pre-mRNA processing factors.

Some of the pathological features of DM are thought to be caused by the mis-regulated alternative splicing of RNA due, at least in part, to the mis-localization of MBNL1 (review in Osborne and Thornton, 2006). The sequestration of other splicing factors involved in early phases of pre-mRNA processing demonstrated by the present study strengthens the idea of a general alteration in the maturation of several mRNAs, which could lead to the multiple pathological dysfunctions observed in dystrophic patients. The occurrence of hnRNPs and snRNPs in some (but not all the) RNA-containing foci suggests that a possible limiting factor for their

sequestration could be the amount of CCUG repeats and/or MBNL1 accumulated therein; taking into account that the severity of the DM2 phenotype relates to the amplification of tetraplet repeats, this opens interesting perspectives for future studies.

Acknowledgments

We are particularly grateful to Prof. C. A. Thornton for providing us with the anti-MBNL1 antibody, and to Prof. T.E. Martin for the anti-hnRNP core protein antibody. Thanks are due to Mrs P. Veneroni for the excellent technical assistance. F.P. is a PhD student in receipt of a fellowship from the Dottorato di Ricerca in Biologia cellulare (University of Pavia). Supported by the University of Pavia (Fondo di Ateneo per la Ricerca, 2008).

References

Bernhard W. A new staining procedure for electron microscopic cytology. *J Ultrastruct Res* 1969;27:250-65.

Biggogera M, Bottone MG, Scovassi AI, Soldani C, Vecchio L, Pellicciari C. Rearrangement of nuclear ribonucleoprotein (RNP)-containing structures during apoptosis and transcriptional arrest. *Biol Cell* 2004;96:603-15.

Biggogera M, Cisterna B, Spedito A, Vecchio L, Malatesta M. Perichromatin fibrils as early markers of transcriptional alterations. *Differentiation* 2007;76:57-65.

Biggogera M., Bottone M.G., Pellicciari C. Nuclear RNA is extruded from apoptotic cells. *J Histochem Cytochem* 1998;46:999-1006.

Biggogera M., Pellicciari C. Heterogeneous Ectopic RNP-Derived Structures (HERDS) are markers of transcriptional arrest. *FASEB J* 2000;14:828-34.

Cardani R, Baldassa S, Botta A, Rinaldi F, Novelli G, Mancinelli E, et al. Ribonuclear inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2. *Neuromuscul Disord* 2009;19:335-43.

Cardani R, Mancinelli E, Rotondo G, Sansone V, Meola G. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2. *Eur J Histochem* 2006;50:177-82.

Cardani R, Mancinelli E, Sansone V, Rotondo G, Meola G. Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. *Eur J Histochem* 2004;48:437-42.

Dere N, Napierala M, Ranum LPW, Wells RD. Hairpin structure-forming property of the (CCTG-CAGG) tetranucleotide repeats contributes to the genetic instability associated with myotonic dystrophy type 2. *J Biol Chem* 2004;279:41715-26.

Fakan S. Ultrastructural cytochemical analyses of nuclear functional architecture. *Eur J Histochem* 2004;48:5-14.

Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshire MG, Harper PS, et al. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. *Hum Mol Gen* 2002;11:805-14.

Holt I, Mittal S, Furling D, Butler-Browne GS, Brook JD, Morris GE. Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles. *Genes Cells* 2007;12:1035-48.

Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. *Hum Mol Gen* 2004;13:3079-88.

Jones RE, Okamura CS, Martin TE. Immunofluorescent localization of the proteins of nuclear ribonucleoprotein complexes. *J Cell Biol* 1980;86:235-43.

Junghans RP. Dystrophya myotonia: why focus on foci? *Eur J Hum Gen* 2009;17:543-53.

Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. *Science* 2001;293:864-7.

Malatesta M, Cardinali A, Battistelli S, Zancanaro C, Martin TE, Fakan S, et al. Nuclear bodies are usual constituents in tissues of hibernating dormice. *Anat Rec* 1999;254:389-95.

Malatesta M, Frigato E, Baldelli B, Battistelli S, Foà A, Bertolucci C. Influence of temperature on the liver circadian clock in the ruin lizard *Podarcis sicula*. *Microsc Res Tech* 2007;70:578-84.

Malatesta M, Luchetti F, Marcheggiani F, Fakan S, Gazzanelli G. Disassembly of nuclear bodies during arousal from hibernation: an in vitro study. *Chromosoma* 2001;110:471-7.

Malatesta M, Zancanaro C, Martin TE, Chan EKL, Amalric F, Lührmann R, et al. Cytochemical and immunocytochemical characterization of nuclear bodies during hibernation. *Eur J Cell Biol* 1994;65:82-93.

Mankodi A, Lin XL, Blaxal BC, Swanson MS, Thornton CA. Nuclear RNA foci in the heart in myotonic dystrophy. *Circ Res* 2005;97:1152-5.

Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, et al. Expanded CUG repeats trigger aberrant splicing of CIC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. *Mol Cell* 2002;10:35-44.

Mankodi A, Teng-Umuay P, Krym M, Henderson D, Swanson M, Thornton CA. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. *Ann Neurol* 2003;54:760-8.

Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, Krym M, et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. *Hum Mol Genet* 2001;10:2165-70.

Margolis JM, Schoser BG, Moseley ML, Day JW, Ranum LP. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. *Hum Mol Genet* 2006;15:1808-15.

Moxley 3rd RT, Meola G, Udd B, Ricker K. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October 2000, Loosdrecht: The Netherlands. *Neuromuscul Disord* 2002;12:306-17.

Osborne RJ, Thornton CA. RNA-dominant diseases. *Hum Mol Genet* 2006;15:R162-9.

Pascual M, Vicente M, Monferrer L, Artero R. The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing. *Differentiation* 2006;74:65-80.

Puvion E, Puvion-Dutilleul F. Ultrastructure of the nucleus in relation to transcription and splicing: roles of perichromatin fibrils and interchromatin granules. *Exp Cell Res* 1996;229:217-25.

Ranum LPW, Day JW. Myotonic Dystrophy: RNA Pathogenesis Comes into Focus. *Am J Hum Genetics*, 2004;74:793-804

Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders. *Annu Rev Neurosci* 2006;29:259-77.

Savkur RS, Philips AV, Cooper TA, Dalton JC, Moseley ML, Ranum LP, et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. *Am J Hum Genet* 2004;74:1309-13.

Schoser BGH, Ricker K, Schneider-Gold C, Hengstenberg C, Dürre J, Bültmann B, et al. Sudden cardiac death in myotonic dystrophy type 2. *Neurology* 2004;63:2402-4.

Spector DL. Nuclear organization and gene expression. *Exp Cell Res* 1996;229:189-97.

Taneja KL, McCurrach M, Schalling M, Housmann D, Singer RH. Foci of trinucleotide repeats in nuclei of myotonic dystrophy cells and tissue. *J Cell Biol* 1995;128:995-1002.

Veraldi KL, Arhin GK, Martincic K, Chung-Ganster LH, Wilusz J, Milcarek C. HnRNP F influences binding of a 64-kilodalton subunit of cleavage stimulation factor to mRNA precursors in mouse B cells. *Mol Cell Biol* 2001;21:1228-38.

Wheeler TM, Krym MC, Thornton CA. Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1. *Neuromuscul Disord* 2007;17:242-7.

Wheeler TM, Thornton CA. Myotonic dystrophy: RNA-mediated muscle disease. *Curr Opin Neurol* 2007;20:572-6.